Approved for use through 10/31/2008, OMB 0661-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSUR	E
STATEMENT BY APPLICAN	ľ
(Not for submission under 37 CFR 1.99)

Application Number		10743563		
Filing Date		2003-12-22		
First Named Inventor	Jean-	Damien Charrier		
Art Unit		1625		
Examiner Name	Zinna	Northington Davis		
Attorney Docket Number		VPI/02-131 US		

Examiner Initial*	Cite No	Patent Number	Kind Code ¹	lssue Date		Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1									
If you wis	h to a	dd additional U.S. Pate	nt citatio	n informa	ation pl	lease click the	Add button.			
			U.S.P	ATENT.	APPLI	CATION PUB	LICATIONS			
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date		Name of Pate of cited Docu	e of Patentee or Applicant ed Document		Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear	
	1	20010042216	A1	2001-11	-15	Myers Bigel Si	bley & Sajovec			
	2	20040242494	A1	2004-12-02		Vertex Pharmaceuticals, Inc.				
If you wisl	h to a	dd additional U.S. Publi	ished Ap	plication	citatio	n information p	olease click the Ad	d butto	on.	
				FOREIG	SN PAT	TENT DOCUM	IENTS			
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² j		Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document Vertex Pharmaceuticals, Inc.		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T5
	1	WO 95/35308			A1	1995-12-28				
	2	EP 0761680	EP		A2	1997-12-03	Ono Pharmaceutical Co., Ltd.		÷	

U.S.PATENTS

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		10743563		
Filing Date		2003-12-22		
First Named Inventor	Jean	n-Damien Charrier		
Art Unit		1625		
Examiner Name	Zinn	Zinna Northington Davis		
Attorney Docket Number		VPI/02-131 US		

	3	WO 97/22619	wo	A2	1997-06-26	Vertex Pharmaceuticals, Inc.			
0	4	WO 2006/057961	wo	A1	2006-06-01	Vertex Pharmaceuticals, Inc.			
If you wish to add additional Foreign Patent Document citation information please click the Add button									
			NON-PATE	NT LITE	RATURE DO	CUMENTS			
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.							
	1	GOLEC, et al., "Structure-Based Design of Non-Peptidic Pyridone Aldehydes as Inhibitors of Interleukin-1β Converting Enzyme", Bioorganic & Medicinal Chemistry Letters (1997), vol. 7, no. 17, pp. 2181 - 2186.							
	2	SEMPLE, et al., "Peptidomimetic Aminomethylene Ketone Inhibitors of Interleukin-18-Converting Enzyme (ICE)", Bioorganic & Medicinal Chemistry Letters (1998), vol. 8, pp. 959-964.							

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

See Kind Codes of USPTO Patent Documents at www_USPTO_GOV or MPEP 901.04. Senter office that issued the document, by the two-letter code (WIPO Standard ST3.). Prior Japanese patent documents, be indicating of the year of the reign of the Emperor must precede the serial number of the patent document, which document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Septicant is to place a check mark here if English language translation is attached.